Semaglutide
Also known as: GLP-1 RA, Ozempic, Wegovy, Rybelsus
Overview
Semaglutide is a GLP-1 receptor agonist approved by regulatory agencies for type 2 diabetes management and chronic weight management. It works by mimicking incretin hormones that regulate blood sugar and appetite.
Benefits
- ✓Weight management support
- ✓Blood sugar regulation (in context of diabetes care)
- ✓Appetite control
- ✓Cardiovascular health benefits
Potential Side Effects
- •Nausea and vomiting
- •Diarrhea or constipation
- •Abdominal pain
- •Decreased appetite
- •Fatigue
- •Injection site reactions (for injectable forms)
Who Should Avoid
- ⚠Pregnant or breastfeeding individuals
- ⚠Those with a personal or family history of medullary thyroid carcinoma
- ⚠People with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- ⚠Individuals with a history of severe gastrointestinal disease
- ⚠Anyone with a known hypersensitivity to semaglutide
Interactions & Precautions
May interact with insulin, sulfonylureas, and other diabetes medications, increasing risk of hypoglycemia. May delay gastric emptying, affecting absorption of oral medications. Discuss all medications with your healthcare provider.
Dosing Information from Literature
For weight management, typical escalation starts at 0.25 mg weekly, gradually increasing to a maintenance dose of 2.4 mg weekly as tolerated. For diabetes, dosing protocols differ. Always follow prescriber guidance.
This is descriptive information only. Always consult a licensed healthcare provider for dosing guidance.
Storage
Unopened pens and vials should be refrigerated. After first use, some formulations may be kept at room temperature for a limited period. Follow manufacturer instructions closely.